RGNX RSI Chart
Last 7 days
3.6%
Last 30 days
-6.0%
Last 90 days
-15.0%
Trailing 12 Months
-13.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 86.7M | 0 | 0 | 0 |
2023 | 109.6M | 97.0M | 99.4M | 90.2M |
2022 | 473.7M | 484.3M | 480.0M | 112.7M |
2021 | 155.8M | 161.3M | 93.1M | 470.3M |
2020 | 52.0M | 60.7M | 144.9M | 154.6M |
2019 | 172.7M | 126.9M | 81.1M | 35.2M |
2018 | 142.3M | 175.8M | 179.8M | 218.5M |
2017 | 4.7M | 8.8M | 10.0M | 10.4M |
2016 | 7.3M | 8.3M | 7.3M | 4.6M |
2015 | 3.8M | 3.6M | 4.3M | 7.6M |
2014 | 6.1M | 6.1M | 6.1M | 6.1M |
2013 | 0 | 0 | 0 | 6.1M |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 15, 2024 | mills kenneth t. | acquired | 56,400 | 3.76 | 15,000 | president and ceo |
Apr 15, 2024 | mills kenneth t. | sold | -272,871 | 18.1914 | -15,000 | president and ceo |
Mar 19, 2024 | vasista vittal | acquired | 75,354 | 3.76 | 20,041 | chief financial officer |
Mar 14, 2024 | mills kenneth t. | acquired | 112,800 | 3.76 | 30,000 | president and ceo |
Mar 14, 2024 | mills kenneth t. | sold | -655,884 | 21.8628 | -30,000 | president and ceo |
Mar 05, 2024 | pakola steve | acquired | 286,536 | 22.25 | 12,878 | chief medical officer |
Mar 05, 2024 | pakola steve | sold | -365,220 | 28.36 | -12,878 | chief medical officer |
Feb 14, 2024 | mills kenneth t. | acquired | 56,400 | 3.76 | 15,000 | president and ceo |
Feb 14, 2024 | mills kenneth t. | sold | -251,349 | 16.7566 | -15,000 | president and ceo |
Jan 16, 2024 | mills kenneth t. | acquired | 169,200 | 3.76 | 45,000 | president and ceo |
Which funds bought or sold RGNX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 17, 2024 | Artal Group S.A. | new | - | 5,267,500 | 5,267,500 | 0.13% |
May 16, 2024 | JANE STREET GROUP, LLC | sold off | -100 | -795,651 | - | -% |
May 16, 2024 | Ancora Advisors LLC | unchanged | - | 3,120 | 21,070 | -% |
May 16, 2024 | COMERICA BANK | reduced | -7.83 | 23,612 | 311,710 | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -1.73 | 115,684 | 869,243 | -% |
May 15, 2024 | QUADRANT CAPITAL GROUP LLC | reduced | -87.69 | -5,989 | 1,012 | -% |
May 15, 2024 | MORGAN STANLEY | reduced | -26.4 | -4,445,470 | 28,230,400 | -% |
May 15, 2024 | JACOBS LEVY EQUITY MANAGEMENT, INC | reduced | -57.95 | -6,318,930 | 6,159,620 | 0.03% |
May 15, 2024 | CITADEL ADVISORS LLC | reduced | -48.83 | -1,520,160 | 2,286,030 | -% |
May 15, 2024 | STATE STREET CORP | added | 18.68 | 18,563,600 | 65,794,000 | -% |
Unveiling REGENXBIO Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to REGENXBIO Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
REGENXBIO Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -29.7% | 15,622,000 | 22,213,000 | 28,914,000 | 19,977,000 | 19,138,000 | 31,345,000 | 26,512,000 | 32,649,000 | 22,218,000 | 398,655,000 | 30,773,000 | 22,035,000 | 18,884,000 | 21,445,000 | 98,912,000 | 16,566,000 | 17,644,000 | 11,768,000 | 14,700,000 | 7,881,000 | 24,329,000 |
Costs and Expenses | -7.7% | 79,485,000 | 86,116,000 | 93,874,000 | 93,085,000 | 85,295,000 | 89,116,000 | 97,557,000 | 95,182,000 | 93,745,000 | 85,059,000 | 88,121,000 | 74,261,000 | 62,926,000 | 75,096,000 | 84,961,000 | 58,399,000 | 55,344,000 | 52,092,000 | 50,596,000 | 44,753,000 | 36,790,000 |
S&GA Expenses | -100.0% | - | 19,079,000 | 23,083,000 | 23,698,000 | 22,634,000 | 21,210,000 | 20,921,000 | 20,832,000 | 22,318,000 | 22,040,000 | 21,030,000 | 18,425,000 | 17,838,000 | 17,571,000 | 15,859,000 | 15,554,000 | 14,833,000 | 14,450,000 | 12,402,000 | 13,405,000 | 11,558,000 |
R&D Expenses | -1.5% | 54,844,000 | 55,681,000 | 58,183,000 | 59,886,000 | 58,516,000 | 62,505,000 | 63,313,000 | 61,008,000 | 55,627,000 | 47,978,000 | 47,855,000 | 45,882,000 | 39,722,000 | 47,180,000 | 43,968,000 | 38,111,000 | 37,035,000 | 33,807,000 | 35,692,000 | 29,483,000 | 25,203,000 |
EBITDA Margin | -4.4% | -2.77 | -2.65 | -2.35 | -2.51 | -2.15 | -2.17 | 0.26 | 0.29 | 0.32 | 0.38 | -2.11 | -0.81 | -0.69 | - | - | - | - | - | - | - | - |
Interest Expenses | 44.8% | 1,973,000 | 1,363,000 | 1,624,000 | 1,120,000 | 2,755,000 | 4,310,000 | 5,954,000 | 6,860,000 | 6,130,000 | 6,500,000 | 6,709,000 | 6,366,000 | 6,702,000 | - | - | - | - | - | - | - | - |
Income Taxes | - | - | - | - | - | - | -43,000 | - | - | -41,000 | 13,403,000 | - | - | 4,000 | 5,743,000 | -3,000 | -500,000 | - | -2,461,000 | -165,000 | -129,000 | 70,000 |
Earnings Before Taxes | 100.0% | - | -63,041,000 | -61,868,000 | -72,061,000 | -66,676,000 | -59,978,000 | -75,484,000 | -68,179,000 | -76,764,000 | 307,426,000 | -58,405,000 | -57,639,000 | -50,135,000 | -40,498,000 | 8,788,000 | -34,262,000 | -40,038,000 | -28,855,000 | -34,749,000 | -1,586,000 | -32,298,000 |
EBT Margin | -4.1% | -3.04 | -2.92 | -2.62 | -2.83 | -2.47 | -2.49 | 0.18 | 0.21 | 0.24 | 0.30 | -2.22 | -0.86 | -0.75 | - | - | - | - | - | - | - | - |
Net Income | -0.7% | -63,330,000 | -62,889,000 | -61,868,000 | -72,061,000 | -66,676,000 | -59,935,000 | -75,484,000 | -68,179,000 | -76,723,000 | 294,023,000 | -58,405,000 | -57,639,000 | -50,139,000 | -46,241,000 | 8,791,000 | -33,762,000 | -40,038,000 | -26,464,000 | -34,584,000 | -1,457,000 | -32,228,000 |
Net Income Margin | -2.7% | -3.00 | -2.92 | -2.62 | -2.83 | -2.47 | -2.49 | 0.15 | 0.19 | 0.21 | 0.27 | -2.28 | -0.90 | -0.78 | - | - | - | - | - | - | - | - |
Free Cashflow | -33.7% | -56,012,000 | -41,886,000 | -50,846,000 | -49,899,000 | -85,736,000 | -44,842,000 | -55,506,000 | -70,986,000 | -66,878,000 | 326,883,000 | -61,201,000 | -55,914,000 | -75,068,000 | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 9.6% | 629 | 574 | 634 | 682 | 748 | 833 | 884 | 953 | 1,025 | 1,114 | 800 | 836 | 879 | 708 | 541 | 450 | 464 | 498 | 509 | 529 | 519 |
Current Assets | 18.0% | 395 | 335 | 366 | 379 | 389 | 416 | 437 | 465 | 447 | 519 | 410 | 437 | 499 | 531 | 387 | 329 | 338 | 345 | 360 | 359 | 304 |
Cash Equivalents | 233.1% | 115 | 35.00 | 53.00 | 69.00 | 70.00 | 97.00 | 119 | 121 | 192 | 345 | 228 | 257 | 291 | 338 | 93.00 | 94.00 | 69.00 | 70.00 | 80.00 | 55.00 | 56.00 |
Net PPE | -3.4% | 128 | 132 | 136 | 139 | 142 | 142 | 141 | 139 | 135 | 132 | 122 | 107 | 89.00 | 56.00 | 39.00 | 33.00 | 30.00 | 29.00 | 28.00 | 27.00 | 23.00 |
Liabilities | -9.0% | 239 | 262 | 271 | 277 | 283 | 317 | 320 | 323 | 336 | 350 | 339 | 329 | 325 | 330 | 126 | 52.00 | 44.00 | 48.00 | 41.00 | 35.00 | 32.00 |
Current Liabilities | -15.4% | 110 | 130 | 127 | 118 | 112 | 130 | 124 | 115 | 120 | 130 | 107 | 92.00 | 84.00 | 81.00 | 64.00 | 40.00 | 32.00 | 34.00 | 31.00 | 25.00 | 21.00 |
Shareholder's Equity | 25.3% | 391 | 312 | 363 | 406 | 465 | 516 | 564 | 631 | 690 | 764 | 461 | 507 | 555 | 378 | 416 | 398 | 420 | 450 | 468 | 495 | 487 |
Retained Earnings | -9.0% | -768 | -705 | -642 | -580 | -508 | -441 | -381 | -306 | -237 | -161 | -455 | -396 | -339 | -289 | -242 | -251 | -217 | -177 | -151 | -116 | -115 |
Additional Paid-In Capital | 13.8% | 1,162 | 1,021 | 1,013 | 996 | 985 | 973 | 964 | 951 | 940 | 928 | 918 | 905 | 895 | 667 | 658 | 649 | 639 | 628 | 619 | 611 | 602 |
Shares Outstanding | 11.3% | 49.00 | 44.00 | 44.00 | 44.00 | 43.00 | 43.00 | 43.00 | 43.00 | 43.00 | 42.00 | 43.00 | 43.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 805 | - | - | - | 985 | - | - | - | 1,310 | - | - | - | 978 | - | - | - | 1,356 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -36.1% | -55,455 | -40,760 | -49,407 | -47,322 | -80,918 | -39,372 | -50,456 | -61,749 | -55,911 | 341,497 | -42,503 | -36,072 | -44,047 | 39,468 | -36,460 | -21,496 | -35,573 | -25,506 | -29,153 | -23,749 | -29,297 |
Share Based Compensation | 15.2% | 9,602 | 8,338 | 10,219 | 10,504 | 11,206 | 9,408 | 10,245 | 10,335 | 10,800 | 9,162 | 9,734 | 9,992 | 9,920 | 7,581 | 8,035 | 8,316 | 8,017 | 6,875 | 7,162 | 7,099 | 5,718 |
Cashflow From Investing | -61.2% | 13,183 | 33,974 | 38,657 | 55,218 | 63,094 | 26,700 | 53,043 | -1,081 | -90,591 | -216,359 | 16,101 | 7,799 | -214,183 | 11,570 | 33,998 | 44,482 | 32,709 | 14,154 | 52,272 | 21,672 | 5,461 |
Cashflow From Financing | 1109.2% | 120,725 | -11,962 | -4,805 | -9,162 | -9,037 | -8,920 | -5,417 | -7,669 | -6,834 | -7,616 | -2,283 | -6,137 | 211,286 | 194,168 | 1,460 | 1,825 | 2,761 | 1,549 | 1,333 | 1,367 | 4,127 |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenues | ||
Revenues | $ 15,622 | $ 19,138 |
Operating Expenses | ||
Cost of revenues | 4,283 | 4,112 |
Research and development | 54,844 | 58,516 |
General and administrative | 18,291 | 22,634 |
Impairment of long-lived assets | 2,101 | |
Other operating expenses (income) | (34) | 33 |
Total operating expenses | 79,485 | 85,295 |
Loss from operations | (63,863) | (66,157) |
Other Income (Expense) | ||
Interest income from licensing | 37 | 70 |
Investment income | 2,469 | 2,166 |
Interest expense | (1,973) | (2,755) |
Total other income (expense) | 533 | (519) |
Net loss | (63,330) | (66,676) |
Other Comprehensive Income | ||
Unrealized gain on available-for-sale securities, net | 1,200 | 3,779 |
Total other comprehensive income | 1,200 | 3,779 |
Comprehensive loss | $ (62,130) | $ (62,897) |
Net loss per share, basic | $ (1.38) | $ (1.53) |
Net loss per share, diluted | $ (1.38) | $ (1.53) |
Weighted-average common shares outstanding, basic | 45,733 | 43,451 |
Weighted-average common shares outstanding, diluted | 45,733 | 43,451 |
License and royalty [Member] | ||
Revenues | ||
Revenues | $ 15,622 | $ 19,138 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 112,975 | $ 34,522 |
Marketable securities | 225,728 | 240,736 |
Accounts receivable, net | 15,828 | 24,790 |
Prepaid expenses | 13,590 | 14,520 |
Other current assets | 27,297 | 20,403 |
Total current assets | 395,418 | 334,971 |
Marketable securities | 41,807 | 38,871 |
Accounts receivable | 523 | 701 |
Property and equipment, net | 127,662 | 132,103 |
Operating lease right-of-use assets | 57,558 | 60,487 |
Restricted cash | 2,030 | 2,030 |
Other assets | 4,217 | 4,807 |
Total assets | 629,215 | 573,970 |
Current liabilities | ||
Accounts payable | 31,356 | 22,786 |
Accrued expenses and other current liabilities | 33,129 | 49,703 |
Deferred revenue | 13 | 148 |
Operating lease liabilities | 7,066 | 7,068 |
Liability related to sale of future royalties | 38,615 | 50,567 |
Total current liabilities | 110,179 | 130,272 |
Operating lease liabilities | 80,183 | 82,222 |
Liability related to sale of future royalties | 44,702 | 43,485 |
Other liabilities | 3,485 | 6,249 |
Total liabilities | 238,549 | 262,228 |
Stockholders’ equity | ||
Preferred stock; $0.0001 par value; 10,000 shares authorized, no shares issued and outstanding at March 31, 2024 and December 31, 2023 | ||
Common stock; $0.0001 par value; 100,000 shares authorized at March 31, 2024 and December 31, 2023; 49,043 and 44,046 shares issued and outstanding March 31, 2024 and December 31, 2023, respectively | 5 | 4 |
Additional paid-in capital | 1,162,267 | 1,021,214 |
Accumulated other comprehensive loss | (3,229) | (4,429) |
Accumulated deficit | (768,377) | (705,047) |
Total stockholders’ equity | 390,666 | 311,742 |
Total liabilities and stockholders’ equity | $ 629,215 | $ 573,970 |